Anfree
(Flupentixol + Melitracen)
Therapeutic Group: Antipsychotic, Neurotonic & Sedative
Generic:
Flupentixol & Melitracen
Presentation:
Anfree Tablet: Each tablet contains Flupentixol Dihyrochloride BP equivalent to Flupentixol 0.5 mg and Melitracen Hydrochloride INN equivalent to Melitracen 10 mg.
Pharmacology:
Flupentixol-a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses, and Melitracen - a bipolar thymoleptic with activating properties in low doses. In combination, the compounds render a preparation with antidepressant, anxiolytic and activating properties.
Maximal serum concentration is reached in about 4 hours after oral administration of Flupentixol and in about 4 hours after oral administration of Melitracen. The biological half-life of Flupentixol is about 35 hours and that of Melitracen is about 19 hours. The combination of Flupentixol and Melitracen does not seem to influence the pharmacokinetic properties of the individual compounds.
Maximal serum concentration is reached in about 4 hours after oral administration of Flupentixol and in about 4 hours after oral administration of Melitracen. The biological half-life of Flupentixol is about 35 hours and that of Melitracen is about 19 hours. The combination of Flupentixol and Melitracen does not seem to influence the pharmacokinetic properties of the individual compounds.
Indication:
Different types of anxiety, depression & apathy. These include- psychogenic depression, depressive neuroses, masked depression, psychosomatic affections accompanied by anxiety and apathy, menopausal depressions, dysphoria and depression in alcoholics and drug-addicts.
Dosage & Administration:
Adults: Usually 2 tablets daily; morning and noon. In severe cases the morning dose may be increased to 2 tablets.
Elderly: 1 tablet in the morning.
Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.
Elderly: 1 tablet in the morning.
Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.
Contraindications:
The immediate recovery phase after myocardial infarction, Defects in bundle-branch conduction, Untreated narrow angle glaucoma, Acute alcohol, barbiturate and opiate intoxications, Flupentixol-Melitracen should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.
Warning & Precautions:
If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.
Side Effects:
In the recommended doses side effects are rare. These could be transient restlessness and insomnia.
Drug interaction:
Flupentixol-melitracen may enhance the response to alcohol, barbiturates and other CNS depressants. Simultaneous administration of MAO-inhibitors may cause hypertensive crises. Neuroleptics and thymoleptics reduce the antihypertensive effect of guanethidine and similar acting compounds and thymoleptics enhance the effects of adrenaline and noradrenaline.
Use in Special group:
Use in pregnancy & lactation: Flupentixol-Melitracen should preferably not be given during pregnancy and lactation.
Packing:
Anfree Tablet: Each box contains 100's tablets in blister pack.
0 comments:
Post a Comment